BioCryst Pharmaceuticals reported $2.7M in Interest Income for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Income Change
Alnylam Pharmaceuticals ALNY:US USD 14.08M 6.26M
BioCryst Pharmaceuticals BCRX:US USD 2.7M 944K
Intra Cellular Therapies ITCI:US USD 3.39M 1.26M
Karyopharm Therapeutics KPTI:US USD 1.33M 676K
Sarepta Therapeutics SRPT:US USD 9.13M 4.35M
Ultragenyx Pharmaceutical RARE:US USD 6.2M 2.72M
Vertex Pharmaceuticals VRTX:US USD 86M 39.8M